Abstract
IntroductionFamily interventions are effective and are strongly recommended for psychotic disorders. However, there is a variety of intervention types, and their differential efficacy is widely unclear. The aim of the planned network meta-analysis (NMA) is to compare the efficacy of family interventions that differ in content (eg, psychoeducation, mutual support, skills training) and format (eg, number of sessions, inclusion of patients, form of delivery).Methods and analysisWe will include randomised controlled trials comparing psychosocial interventions directed at the adult relatives, friends or non-professional carers of people with a diagnosis of a psychotic disorder (schizophrenia spectrum) to any kind of control condition. The main outcomes will be global clinical state for the patients and coping with psychosis as well as attitudes towards psychosis for the relatives. Additional outcomes will be severity of symptoms, functioning, burden and compliance/drop-out. We conducted a comprehensive search of Cochrane Central Register of Controlled Trials, MEDLINE(R), PsycINFO, Cumulative Index to Nursing & Allied Health Literature (8 August 2019) and reference lists of review articles. Full-text assessment of eligibility, data extraction and risk-of-bias assessment will be done by two independent reviewers. An NMA will be conducted for any of the planned outcomes and intervention characteristics for which sufficient and appropriate data are available. The analyses will make use of a random effects model within a frequentist framework. Estimates for all pairwise treatment effects will be obtained using standardised mean differences for continuous outcomes and risk ratios for dichotomous outcomes. Interventions will be ranked according to their relative efficacy. We will address the assumption of transitivity, heterogeneity and inconsistency using theoretical and statistical approaches. The possibility of publication bias and the strength of evidence will also be examined.Ethics and disseminationThere are no ethical concerns. Results will be published in peer-reviewed journals and presented at practitioners’ conferences.PROSPERO registration numberCRD42020148728.
Reference47 articles.
1. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis
2. Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
3. Lincoln TM , Pedersen A , Hahlweg K . Evidenzbasierte Leitlinie zur Psychotherapie von Schizophrenie und anderen psychotischen Störungen. Göttingen, Germany: Hogrefe, 2019.
4. National Collaborating Centre for Mental Health (NCCMH) . Psychosis and schizophrenia in adults: the NICE guideline on treatment and management. Updated edition 2014. London, U.K.: National Institute for Health and Care Excellence, 2014.
5. DGPPN e.V. for the Guideline Group, editor . S3 guideline for schizophrenia. Abbreviated version (English), version 1.0, 2019. Available: https://www.awmf.org/leitlinien/detail/ll/038-009.html [Accessed 17 Sep 2020].
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献